[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549978":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":19,"responsibleParty":31,"collaborators":33,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":19,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":19,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":58,"whyStopped":19,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":19},{"fullName":5,"class":6},"Nuwacell Biotechnologies Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"NCR300 injection","EXPERIMENTAL","Cohort1: Low dose NCR300 injection; Cohort2: Mid-low dose NCR300 injection; Cohort3: Mid-high dose NCR300 injection; Cohort4: High dose NCR300 injection.",[13],"Biological: NCR300 injection",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Subjects will receive at least 1 cycle of NCR300 injection.",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Zhao Wang, Doctor","Capital Medical University","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Xiaowen Gong","CONTACT","15221195602","xwgong@nuwacell.com",{"type":32,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[34],{"name":35,"class":36},"Beijing Friendship Hospital","OTHER","100549978","phase-1-a-trial-to-evaluate-the-safety-and-efficacy-of-ncr300-in-preventing-recurrence-of-acute-myeloid-leukemiaaml-after-transplantation-100549978",false,"NCT06441084","A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation","A Phase I or II Clinical Trial Evaluating the Safety and Efficacy of NCR300 Injection in Preventing Recurrence of Acute Myeloid Leukemia After Allogeneic Blood Stem Cell Transplantation","Inclusion Criteria:\n\n1.Subjects who understand and voluntarily sign the Informed Consent Form(ICF);\n\n2.18-65years;\n\n3.Clinical diagnosis of AML;\n\n4.Accepted allogeneic blood stem cell transplantation within 60 to 28 days prior before initial infusion;\n\n5.Complete donor chimerism and with high-risk recurrence factors prior to transplantation , or bone marrow examination shows positive MRD；\n\n6.Have already recovered from the adverse reactions of previous treatment；\n\n7.Having appropriate organ functions；\n\n8.Eastern Cooperative Oncology Group(ECOG)\\\u003C3;\n\n9.Subjects who are able to comply with contraceptives from the study period to 6 months after the end of this study;\n\nExclusion Criteria:\n\n1. Bone marrow examination shows hematological recurrence;\n2. Have malignant tumors within 5 years before screening;\n3. Subjects with acute promyelocytic leukemia(APL);\n4. Subjects with severe respiratory diseases;\n5. Subjects with clear history of neurological or psychiatric disorders in the past;\n6. Active central nervous system involvement；\n7. HIV(human immunodeficiency virus) antibody positive,treponema pallidum(TP) antibody positive.Have active hepatitis B or hepatitis C;\n8. Allergies to NCR300 or its excipients;\n9. Subjects with active cardiovascular and cerebrovascular diseases;\n10. Received organ transplantation or planned transplantation；\n11. Received other treatment drugs after transplantation；\n12. Graft-Versus-Host Disease (GVHD)\\>II grades;\n13. Subjects with active nervous system autoimmune or inflammatory diseases;\n14. Expected survival period within 3 months;\n15. Have alcohol or drug addiction or with a clear history of mental disorders or with a history of drug abuse or drug use of psychotropic substances;\n16. Having mental illness；\n17. Having uncontrollable active infections;\n18. Subjects whose state is not suitable for entering the study;\n19. Other situations determined by investigator that it is not suitable to enter the study.","ALL","18 Years","65 Years",{"count":48,"type":49},15,"ESTIMATED","INTERVENTIONAL",[52],"PHASE1","A Trial to Evaluate the Safety and Efficacy of iNK in the Treatment of Subjects for Preventing Recurrence of Acute Myeloid Leukemia After Allogeneic Blood Stem Cell Transplantation.",[55],"Acute Myeloid Leukemia",[57],"iNK","NOT_YET_RECRUITING","2024-06-02",{"date":61,"type":62},"2024-06-04","ACTUAL",{"date":64,"type":49},"2024-06-30",{"date":66,"type":49},"2031-12-31",{"name":5,"class":6}]